MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Integer Divests AS&O Business to MedPlast for $600M

Integer will now turn its attention to its Cardio & Vascular and Cardiac & Neuromodulation offerings.

Integer Holdings Corp. is stepping away from one of its core businesses to invest more in its Cardio & Vascular and Cardiac & Neuromodulation offerings. The Frisco, TX-based company said it is divesting its Advanced Surgical and Orthopedics (AS&O) unit to MedPlast for $600 million. The acquisition is set to close in the third quarter of this year.

Integer’s AS&O capabilities will bolster MedPlast’s portfolio of manufacturing solutions. In addition to expanding MedPlast’s offering into a broad range of metals manufacturing capabilities, including machining, stamping, coating, and metal forming, it will further strengthen MedPlast’s front-end design, development and prototyping services.

“This transaction positions Integer to more aggressively invest to grow our Cardiac & Vascular - Cardio & Vascular and Cardiac & Neuromodulation product lines, where we have clear leadership positions,” said Joseph Dziedzic, president and CEO of Integer, according to a Seeking Alpha transcript.

MedPlast is acquiring about $400 million in sales based on 2017 financials, along with 10 manufacturing facilities. Integer sales will only decrease by about $350 million because it will continue to supply MedPlast about $50 million of product.

“We will have greater financial flexibility, and our evaluation metrics improve,” Dziedzic said. “After the transaction, we expect our margins to expand by at least 20 basis points. We plan to use the sale of proceeds to repay about $550 million of debt, which will reduce our leverage to less than four times EBITDA.”

Integer is realigning its focus in a way much similar to LivaNova. The London-based company sold its Cardiac Rhythm and Management Unit to Microport for $190 million in cash, last year to focus on its cardiac surgery and neuromodulation businesses.

Filed Under
500 characters remaining